Ultrasound in medicine & biology · 2026
Evaluation of the Efficacy of Combined Treatment of Liver Cancer With Losartan and Ultrasound‑Stimulated Microbubble Cavitation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Xiaojing, Numata Kazushi, Zhang Jie, Wu Zheng, Zhang Wenbin, Wang Feiqian
Аннотация
OBJECTIVES: To investigate the combined therapeutic effects of "mechanotherapeutic" agent losartan and ultrasound-stimulated microbubble cavitation (USMC) on hepatocellular carcinoma (HCC).
METHODS: C57BL/6 mice were assigned to five groups: losartan only, USMC only, combination (losartan+USMC), untreated HCC, and healthy controls. HCC was induced via intrahepatic implantation of Hepa1-6 cells at 6 weeks. Losartan was administered every other day. USMC was delivered five times (three sessions with low mechanical index (MI) followed by two sessions with high MI). Ultrasound resolution microscopy (URM) and ultrasound viscoelastic imaging (UVI) were performed before the first and after the last USMC treatment. URM quantified microvascular density, density ratio, blood-flow velocity, and perfusion index; UVI assessed elasticity, viscosity, and dispersion coefficients. Tumor volume, liver/body weight, and CD34 staining were analyzed at sacrifice.
RESULTS: After USMC treatment, mean blood-flow velocity increased in combination group (9.7 ± 2.00 to 13.1 ± 1.59 mm/s, p = 0.006) and microvascular density, density ratio, and perfusion index reduced in USMC-treated groups. Viscoelasticity in three treated groups decreased after treatment and remained lower than untreated HCC but higher than healthy controls, with significant decline in the combination group (elasticity p = 0.006; viscosity p = 0.028; dispersion p < 0.001). Tumor volume was significantly reduced in all treated groups (p < 0.001). CD34 staining showed lower microvascular positivity in the USMC and combination groups.
CONCLUSIONS: Low- and high-MI USMC enhanced vascular permeability and induced vascular disruption, while losartan reduced stromal stiffness. Their combination produced additive therapeutic effects on HCC. URM and UVI provide complementary, noninvasive assessment of vascular and mechanical responses during mechanotherapeutic and cavitation-based treatments.
METHODS: C57BL/6 mice were assigned to five groups: losartan only, USMC only, combination (losartan+USMC), untreated HCC, and healthy controls. HCC was induced via intrahepatic implantation of Hepa1-6 cells at 6 weeks. Losartan was administered every other day. USMC was delivered five times (three sessions with low mechanical index (MI) followed by two sessions with high MI). Ultrasound resolution microscopy (URM) and ultrasound viscoelastic imaging (UVI) were performed before the first and after the last USMC treatment. URM quantified microvascular density, density ratio, blood-flow velocity, and perfusion index; UVI assessed elasticity, viscosity, and dispersion coefficients. Tumor volume, liver/body weight, and CD34 staining were analyzed at sacrifice.
RESULTS: After USMC treatment, mean blood-flow velocity increased in combination group (9.7 ± 2.00 to 13.1 ± 1.59 mm/s, p = 0.006) and microvascular density, density ratio, and perfusion index reduced in USMC-treated groups. Viscoelasticity in three treated groups decreased after treatment and remained lower than untreated HCC but higher than healthy controls, with significant decline in the combination group (elasticity p = 0.006; viscosity p = 0.028; dispersion p < 0.001). Tumor volume was significantly reduced in all treated groups (p < 0.001). CD34 staining showed lower microvascular positivity in the USMC and combination groups.
CONCLUSIONS: Low- and high-MI USMC enhanced vascular permeability and induced vascular disruption, while losartan reduced stromal stiffness. Their combination produced additive therapeutic effects on HCC. URM and UVI provide complementary, noninvasive assessment of vascular and mechanical responses during mechanotherapeutic and cavitation-based treatments.